IN2014DN08398A - - Google Patents

Info

Publication number
IN2014DN08398A
IN2014DN08398A IN8398DEN2014A IN2014DN08398A IN 2014DN08398 A IN2014DN08398 A IN 2014DN08398A IN 8398DEN2014 A IN8398DEN2014 A IN 8398DEN2014A IN 2014DN08398 A IN2014DN08398 A IN 2014DN08398A
Authority
IN
India
Prior art keywords
biomarker
parkinson
disease
drug
relates
Prior art date
Application number
Inventor
Dario Alessi
Muratul Muqit
Original Assignee
Univ Dundee
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Dundee filed Critical Univ Dundee
Publication of IN2014DN08398A publication Critical patent/IN2014DN08398A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette

Abstract

The present invention relates to a biomarker for Parkinson s disease. The biomarker and products associated with the biomarker may be used to assist diagnosis or to assess onset and/or development of Parkinson s disease. The invention also relates to use of the biomarker in clinical screening assessment of prognosis evaluation of drug treatments drug screening or drug development in the field of Parkinson s disease and Parkinson s disease related disorders.
IN8398DEN2014 2012-04-11 2013-04-10 IN2014DN08398A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201206382A GB201206382D0 (en) 2012-04-11 2012-04-11 Parkinson's disease biomarker
PCT/GB2013/050926 WO2013153386A1 (en) 2012-04-11 2013-04-10 Parkinson's disease biomarker

Publications (1)

Publication Number Publication Date
IN2014DN08398A true IN2014DN08398A (en) 2015-05-08

Family

ID=46177150

Family Applications (1)

Application Number Title Priority Date Filing Date
IN8398DEN2014 IN2014DN08398A (en) 2012-04-11 2013-04-10

Country Status (5)

Country Link
US (1) US20150104806A1 (en)
EP (1) EP2836842A1 (en)
GB (1) GB201206382D0 (en)
IN (1) IN2014DN08398A (en)
WO (1) WO2013153386A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3109636B1 (en) * 2014-02-18 2018-10-31 Tokyo Metropolitan Institute of Medical Science Biomarker for parkinson's disease and use therefor
US11214774B2 (en) * 2015-05-01 2022-01-04 Andrew Man Chung Wo PINK1 C-terminal domain polypeptide and methods using the same in cancer treatment
GB201516342D0 (en) * 2015-09-15 2015-10-28 Univ Dundee Downstream targets of PINK1
US11360102B2 (en) 2015-09-23 2022-06-14 Boston Medical Center Corporation Biomarkers for the early detection of Parkinson's disease
CA3071824A1 (en) * 2017-08-01 2019-02-07 Cove Bio Llc Biomarkers associated with parkinson's disease
CN113227788B (en) * 2019-03-19 2023-11-21 中南大学湘雅医院 Method and reagent for auxiliary diagnosis and treatment of parkinsonism

Also Published As

Publication number Publication date
WO2013153386A1 (en) 2013-10-17
US20150104806A1 (en) 2015-04-16
EP2836842A1 (en) 2015-02-18
GB201206382D0 (en) 2012-05-23

Similar Documents

Publication Publication Date Title
WO2013066764A3 (en) Alzheimer's disease signature markers and methods of use
IN2014DN08398A (en)
NZ735173A (en) Biomarkers for the diagnosis and/or prediction of susceptibility to mental and neurodegenerative disorders
EP3464638A4 (en) Use of biomarkers in determining susceptibility to disease treatment
MX2016002423A (en) Diagnostic methods and compositions for treatment of glioblastoma.
WO2015094995A3 (en) Gene signature biomarkers of tumor response to pd-1 antagonists
EP3060913A4 (en) Biomarkers and diagnostic methods for alzheimer's disease and other neurodegenerative disorders
WO2014140254A9 (en) Improved user interface for acquistion, display and analysis of ophthalmic diagnostic data
MX356802B (en) Biological markers for identifying patients for treatment with vegf antagonists.
BR112013010015A2 (en) apparatus and method for noninvasive detection of diseases affecting the structural properties of biological tissues
IL246917A0 (en) Biomarker and methods for early diagnosis of alzheimer's disease
BR112013022493A2 (en) equipment and method for examining, diagnosing or assisting in the diagnosis and treatment of functional vision problems
MX358474B (en) Specific salivary biomarkers for risk detection, early diagnosis, prognosis and monitoring of alzheimer's and parkinson's diseases.
WO2012173976A3 (en) Methods and apparatus for assessing activity of an organ and uses thereof
WO2015013508A3 (en) Methods for diagnosing and treating immune disease
BR112014014960A2 (en) Methods for Diagnosing Alzheimer's Disease
NZ716643A (en) Methods for predicting the risk of having a cardiovascular event and for monitoring the treatment of a cardiovascular event
NZ729773A (en) Biomarkers for disease progression in melanoma
PH12017502099A1 (en) Methods for diagnosing and assessing treatment for cushing's syndrome
IN2014DN08537A (en)
BR112015027249A2 (en) cancer diagnosis method
WO2014052685A3 (en) Devices and methods for single cell analysis
MX2017001293A (en) Methods and compositions for diagnosing and treating inflammatory bowel disorders.
IN2014DN08312A (en)
MX364003B (en) Treatment of insulin resistance through inhibitors of transcription factor tsc22d4.